BioCryst to Report Third Quarter 2022 Financial Results on November 1
BioCryst Pharmaceuticals (BCRX) announced it will report its Q3 2022 financial results on November 1, 2022.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BioCryst Pharmaceuticals (BCRX) announced it will report its Q3 2022 financial results on November 1, 2022. A conference call and webcast will be held at 8:30 a.m. ET to discuss the results and provide a corporate update. The call can be accessed by dialing 866-374-5140 domestically or 404-400-0571 internationally, using conference ID 28663801#. Additionally, a live webcast will be available on the BioCryst website, along with a replay post-call.
Positive
- Scheduled release of Q3 2022 financial results indicates ongoing transparency with shareholders.
- The conference call provides an opportunity for investors to gain insights directly from management.
Negative
- None.
Details
News Market Reaction – BCRX
The recorded move for BCRX in the trading session of this news was +0.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., Oct. 18, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2022 financial results Tuesday, November 1, 2022.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 866-374-5140 for domestic callers and 404-400-0571 for international callers and using conference ID 28663801#. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A replay of the call will be available on the company website.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and multiple global markets. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and yellow fever. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.
BCRXW
Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com
Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.